Pregnancy Outcomes in Females with Eosinophilic Esophagitis: A Nationwide Population-Based Study.

Autor:	Röjler L; Department of Pediatrics, Örebro University Hospital, Örebro, Sweden., Uchida AM; Division of Gastroenterology, Hepatology and Nutrition, University of Utah School of Medicine, Salt Lake City, UT, USA.; Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Garber JJ; Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Stephansson O; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Söderling J; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Roelstraete B; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Ludvigsson JF; Department of Pediatrics, Örebro University Hospital, Örebro, Sweden.; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Jazyk:	angličtina
Zdroj:	Inflammatory intestinal diseases [Inflamm Intest Dis] 2023 Oct 05; Vol. 8 (4), pp. 143-152. Date of Electronic Publication: 2023 Oct 05 (Print Publication: 2023).
DOI:	10.1159/000534412
Abstrakt:	Introduction: Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus. It has a peak incidence in the 2nd and 3rd decades of life. Despite this, little is known about pregnancy outcomes in patients with EoE. Methods: Using a validated histopathologic and nationwide population-based cohort for the diagnosis of EoE, we examined maternal and fetal outcomes, with preterm birth as the primary outcome, in females with EoE compared to matched controls. Odds ratios (ORs) were calculated using logistic regression. Results: Between 1992 and 2016, we identified 19 females with EoE who gave birth to 23 children (reference births: n = 115). There was 1 (4.3%) preterm birth in the EoE cohort versus 8 (7.0%) in the reference cohort (OR = 0.60; 95% CI = 0.07-5.14). Secondary fetal outcomes included stillbirth, neonatal death, small for gestational age, low birth weight (LBW), and low Apgar score. Of these, LBW (<2,500 g) in patients with EoE compared to controls correlated to an OR of 12.42 (95% CI = 1.26-122.42); however, this finding was based on very low numbers. The remaining fetal outcomes were not significantly different between females with EoE and controls. Secondary pregnancy and maternal outcomes including induction of labor, instrumental delivery, gestational diabetes, or pre-eclampsia were not significantly different between patients with EoE and controls. Discussion/conclusion: Overall in this nationwide cohort study, we did not find increased association of preterm birth in patients with EoE. Competing Interests: Dr. Uchida is on a Medical Advisory Board for Sanofi-Genzyme (unrelated to this study) and AstraZeneca. Dr. Garber has received research support from the American Partnership for Eosinophilic Disorders (APfED) and Takeda Pharmaceuticals. None of those studies have any relation to the present study. Dr. Ludvigsson coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). That study has received funding from Janssen corporation. (© 2023 The Author(s). Published by S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu